No Data
Atea Pharma Presents Results From Full Cohort Of Patients Enrolled In Phase 2 Study Evaluating Once-daily Combination Of BEM And RZR For Treatment Of Hepatitis C Virus
Earnings Preview: AVIR to Report Financial Results Post-market on May 12
Atea Pharmaceuticals to Host Hepatitis C Virus KOL Panel
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
Atea Pharmaceuticals Says Strategic Alternatives Process 'Ongoing'
Atea Pharmaceuticals Appoints Howard Berman to Board of Directors